University of Miami Health System, Miller School of Medicine

New Cell Therapy Trial Launches for Patients with Severe COVID-19

FDA grants immediate authorization for clinical trial to test umbilical cord-derived mesenchymal stem cells in COVID-19 patients.

Newswise — An international team of scientists led by Camillo Ricordi, M.D., director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine, has been granted immediate FDA authorization for a 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells to block the life-threatening lung inflammation that accompanies severe cases of COVID-19.

“There is no time to waste,” said Dr. Ricordi, the principal investigator, who is the Stacy Joy Goodman Professor of Surgery. “Patients who die from COVID-19 have a median time of just 10 days between first symptoms and death. In severe cases oxygen levels in the bloodstream drop, and the inability to breathe pushes patients toward their end very quickly; any intervention that might prevent that trajectory would be highly desirable.”

The trial will be based at the University of Miami Health System and Jackson Health System. It is the result of a collaborative academic initiative sponsored by The Cure Alliance, a non-profit group of scientists and innovators dedicated to sharing knowledge and accelerating cures for all diseases. In response to the COVID-19 pandemic, The Cure Alliance has pivoted all resources to fighting the virus. The clinical protocol has been shared with other academic institutions throughout the world who want to test similar treatment strategies in the fastest and most efficient way possible.

“We are very grateful to the FDA’s Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, for performing four rounds of reviews in a record time — one week,” said Dr. Ricordi.

The FDA had previously authorized the testing of umbilical cord-derived mesenchymal stem cell products in patients with type 1 diabetes and Alzheimer’s disease at the University of Miami as part of other clinical trials. For the COVID-19 trial, Dr. Ricordi enlisted additional experts from around the world with extensive experience in infectious diseases, pulmonary medicine and critical care, while others provided expertise in cell-based product development and their use in clinical trials. The cell therapy is administered intravenously.




Filters close

Showing results

110 of 2448
Released: 2-Jul-2020 11:50 AM EDT
New Study Explains Potential Causes for “Happy Hypoxia” Condition in COVID-19 Patients
Loyola Medicine

A new research study provides possible explanations for COVID-19 patients who present with extremely low, otherwise life-threatening levels of oxygen, but no signs of dyspnea (difficulty breathing). This new understanding of the condition, known as silent hypoxemia or “happy hypoxia,” could prevent unnecessary intubation and ventilation in patients during the current and expected second wave of coronavirus.

Released: 2-Jul-2020 10:15 AM EDT
Stemming the Spread of Misinformation on Social Media
Association for Psychological Science

New research reported in the journal Psychological Science finds that priming people to think about accuracy could make them more discerning in what they subsequently share on social media.

29-Jun-2020 9:00 AM EDT
Coronavirus damages the endocrine system
Endocrine Society

People with endocrine disorders may see their condition worsen as a result of COVID-19, according to a new review published in the Journal of the Endocrine Society.

Released: 2-Jul-2020 8:50 AM EDT
Learn from the pandemic to prevent environmental catastrophe, scientists argue
University of Cambridge

• COVID-19 is comparable to climate and extinction emergencies, say scientists from the UK and US – all share features such as lagged impacts, feedback loops, and complex dynamics. • Delayed action in the pandemic cost lives and economic growth, just as it will with environmental crises – but on a scale “too grave to contemplate”.

Released: 1-Jul-2020 5:30 PM EDT
COVID-19 seed grants awarded to 7 ISU research projects
Iowa State University

Iowa State's COVID-19 Research Seed Grant program will support the initial stages of high-risk/high-reward projects that address the COVID-19 crisis.

Released: 1-Jul-2020 4:30 PM EDT
National Survey on COVID-19 Pandemic Shows Significant Mental Health Impact
Beth Israel Deaconess Medical Center

The findings of a nationwide survey assessing the effects of the COVID-19 pandemic on the emotional wellbeing of U.S. adults show 90 percent of survey respondents reported experiencing emotional distress related to the pandemic.

Released: 1-Jul-2020 2:40 PM EDT
Surveys Reveal Significant Shifts in Consumer Behavior During Pandemic
Rensselaer Polytechnic Institute (RPI)

The COVID-19 pandemic has significantly altered how people shop, how much they buy, the trips they take outside their homes, and the number of tele-activities — like work, medicine, and education — that have become commonplace. These changes were rapid and have tremendously impacted the economy, supply chains, and the environment. Two sets of surveys were conducted by researchers at Rensselaer Polytechnic Institute in an effort to quantify and understand these unprecedented shifts — and evaluate the likelihood they may last after the pandemic has ended.

Released: 1-Jul-2020 2:20 PM EDT
COVID-19 Fatality Risk Is Double Earlier Estimates: Study
Columbia University, Mailman School of Public Health

In one of the most robust studies of COVID-19 mortality risk in the United States, researchers estimate an infection fatality rate more than double estimates from other countries, with the greatest risk to older adults. Columbia University Mailman School of Public Health scientists and New York City Department of Health and Mental Hygiene colleagues published the findings on the pre-print server medRxiv ahead of peer review.

Released: 1-Jul-2020 2:15 PM EDT
Study Examines Limiting School Capacity for New York City Reopening
Columbia University, Mailman School of Public Health

Data modeling projections by Columbia University Mailman School of Public Health scientists evaluate potential policies to reduce new infections, hospitalizations, and deaths in coming months, including by limiting school capacity by 50 percent or capping capacity of certain industries to 25 percent during Phase Four, as well as by implementing an “adaptive PAUSE” system to re-implement social distancing rules during a rebound. The researchers have been working with the New York City Department of Health and Mental Hygiene on COVID-19 planning. Their new report is posted on Github.


Showing results

110 of 2448

close
0.79561